)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Iterum Therapeutics
Iterum Therapeutics (ITRM) investor relations material
Iterum Therapeutics has been delisted
Iterum Therapeutics Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy Filing summary13 Feb, 2026
Executive summary
Extraordinary general meeting scheduled for February 18, 2026, with four proposals up for shareholder vote.
Board of directors and major proxy advisory firms unanimously recommend voting in favor of all proposals.
Voting is encouraged online or by phone, with a deadline of February 17, 2026, at 11:59 PM ET for remote participation.
Voting matters and shareholder proposals
Four proposals are on the agenda, as detailed in the definitive proxy statement filed January 2, 2026.
Shareholders are urged to vote regardless of the number of shares owned.
Institutional Shareholder Services and Glass Lewis both recommend voting for all proposals.
Board of directors and corporate governance
Board of directors has unanimously recommended approval of all proposals.
Communication to shareholders signed by the President and CEO.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Iterum Therapeutics
- First FDA-approved oral penem for UUTIs shows strong early adoption and long-term market protection.ITRM
Investor presentation - Four key proposals up for vote at the February 2026 EGM, with full board support.ITRMProxy Filing
- ORLYNVAH™ launches as the first oral penem for UUTIs, addressing urgent resistance challenges.ITRMInvestor Presentation
- EGM to vote on capital increase, share issuance authority, pre-emption opt-out, and reverse split.ITRMProxy Filing
- ORLYNVAH launches in August 2025, with cash runway into 2026 but more funding needed.ITRMQ2 2025
- Orlynvah gains FDA approval and exclusivity, but urgent funding and strategic action are needed.ITRMQ3 2024
- FDA approves Orlynvah, a novel oral penem, for hard-to-treat uUTIs in adult women.ITRMFDA Announcement
- Sulopenem approaches FDA approval as the first oral penem for UTIs, with partnership plans ahead.ITRMMaxim Group’s 2024 Healthcare Virtual Summit
- Q2 net loss narrowed, cash runway extended, and FDA review of sulopenem advances.ITRMQ2 2024
Iterum Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing novel anti-infective therapies. The company is working on next-generation oral and intravenous antibiotics designed to combat infections caused by multi-drug resistant pathogens, which are a growing global health concern. Iterum's lead product candidate, sulopenem, is a novel penem antibiotic that has shown potent activity against a broad spectrum of bacteria, including strains that are resistant to other antibiotics. Iterum Therapeutics is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.